NCT06126081Active, not recruiting
Clinical Efficacy of Early Left Bundle Branch Pacing for Cardiac Resynchronization Therapy
Clinical Efficacy of Early Left Bundle Branch Pacing for Cardiac Resynchronization Therapy Compared With Guideline-directed Medical Therapy in Heart Failure With Mild-reduced Ejection Fraction.
Source: ClinicalTrials.gov · Last updated 31 Mar 2026
Brief summary (registry, in English)
This is a two-center, prospective randomized controlled trial. The aim of this study is to compare the clinical efficacy of early left bundle branch pacing for cardiac resynchronization therapy and guideline-directed medical therapy in heart failure with mild-reduced ejection fraction.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- First submitted
- 5 Sept 2023
- Start date
- 26 Jun 2023
- Primary completion date
- Jun 2026
- Lead sponsor
- Fu Wai Hospital, Beijing, China
- Diseases
- Heart failure
- NCT number
- NCT06126081
What you commit to
- Study type: Interventional
- Planned participants: 36
- From 26 Jun 2023 to the primary completion date, Jun 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Indicated for ICD or pacing therapy;
Other illness
- History of VT, VF, or hemodynamic instability;
- History of mechanical tricuspid valve replacement;
- Severe structural heart disease may necessitate cardiac surgery or heart transplantation within 1 year;
Lab values
- Severe renal dysfunction (eGFR \< 15ml/min\*1.73m\^2).
Other
- Expected survival less than 24 months;
- Ischemic cardiomyopathy scheduled for CABG and PCI within 3 months;
- Pregnancy or planning for pregnancy;
- Hypertrophic cardiomyopathy or those underwent ventricular septal defect repair, in whom the success of LBBP is anticipated to be challenging;
Who the study is looking for
- Age ≥ 18 years;
- symptomatic heart failure despite guideline-directed medical therapy for at least 3 months, NYHA class II-IV, with an EF between 35% and 50%;
- complete LBBB meeting Strauss's standard definition
- Signed informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
| The First Affiliated Hospital of Nanjing Medical University Coordinator of this site? Confirm its status | Nanjing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.